TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22168398

Group type: COMPARATOR
Intervention: 0 mg bupropion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg bupropion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 200 mg bupropion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 8
Study: 18846473

Group type: EXPERIMENTAL
Intervention: Residential Cognitive Therapy (RCT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Residential Interpersonal Therapy (RIPT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Common process factors
Number of subjects: 80
Study: 17485628

Group type: EXPERIMENTAL
Intervention: Pityriasis rosea in black children
Number of subjects: 50
Study: 15315717

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg, single oral dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d, repeated dosing for 2 weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11449834

Group type: EXPERIMENTAL
Intervention: Multidisciplinary pain treatment (MPT)
Number of subjects: 189

Group type: COMPARATOR
Intervention: General practice (GP group)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Waiting list group (WL group)
Number of subjects: 189
Study: 10399516

Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine plus 25 micrograms fentanyl (0.5 ml) and cerebrospinal fluid (CSF) 0.6 ml (Group M + F)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 8 mg hyperbaric bupivacaine plus 0.5 ml of CSF (Group M)
Number of subjects: 30
Study: 8002551

Group type: EXPERIMENTAL
Intervention: Overtraining group (OT); weight trained legs daily for 2 weeks with 100% 1 repetition maximum
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Overtraining group (OT); exercise-induced concentrations of epinephrine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Overtraining group (OT); exercise-induced concentrations of norepinephrine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group; exercised 1 day/wk with low relative intensity (50% 1 repetition maximum)
Number of subjects: 17
Study: 3244794

Group type: EXPERIMENTAL
Intervention: 25 mg PLG i.v.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29897022

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 27477844

Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine (100μg adjuvanted with aluminum hydroxide)
Number of subjects: 1849

Group type: COMPARATOR
Intervention: Control vaccine (rabies)
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine
Number of subjects: 1849
Study: 26376397

Group type: EXPERIMENTAL
Intervention: PRD (propofol/remifentanil/dexmedetomidine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: PRS (propofol/remifentanil/saline)
Number of subjects: 80
Study: 23698199

Group type: EXPERIMENTAL
Intervention: 0.2% levobupivacaine with 2 Mi g/ml fentanyl
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.1% levobupivacaine with 2 Mi g/ml fentanyl
Number of subjects: 50
Study: 20861739

Group type: EXPERIMENTAL
Intervention: ramelteon (8 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 17548076

Group type: EXPERIMENTAL
Intervention: Metformin 2000 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Metformin and Placebo
Number of subjects: 63
Study: 16972407

Group type: EXPERIMENTAL
Intervention: 30 degree reverse Trendelenburg's position
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine-horizontal position
Number of subjects: 40
Study: 11821201

Group type: EXPERIMENTAL
Intervention: Axial length measurement using the prototype PCI instrument (ALM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Axial length measurement using immersion ultrasound (IUS)
Number of subjects: 45
Study: 9892876

Group type: EXPERIMENTAL
Intervention: pumaprazole (100 mg b.d.)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: omeprazole (20 mg o.d.)
Number of subjects: 13

Group type: COMPARATOR
Intervention: pumaprazole
Number of subjects: 13
Study: 7735594

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 5 ppm
Number of subjects: 13
Study: 2248835

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.1 MAC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.2 MAC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.4 MAC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.2 MAC and greater
Number of subjects: 8

Group type: COMPARATOR
Intervention: 100% Oxygen
Number of subjects: 8
Study: 7023648

Group type: EXPERIMENTAL
Intervention: Patient's history classified according to growth rate
Number of subjects: 756

Group type: COMPARATOR
Intervention: Other prognostic factors (stage, lymph node status, tumor grade)
Number of subjects: 756
Study: 30697661

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30635940

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study: 28139938

Group type: EXPERIMENTAL
Intervention: Alt‐RAMEC protocol for 5 weeks (Group 1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Alt‐RAMEC protocol for 9 weeks (Group 2)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 34
Study: 26536019

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/day initially and 20 mg/day at the end of the first week)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 23314272

Group type: EXPERIMENTAL
Intervention: Peptide/CAF01 vaccine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21980373

Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400 mg)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Single-dose mebendazole (500 mg)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Triple-dose albendazole (3×400 mg over 3 consecutive days)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Triple-dose mebendazole (3×500 mg over 3 consecutive days)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Triple-dose mebendazole
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Single and triple doses of either drug
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Triple-dose regimens
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Single-dose regimens
Number of subjects: 314
Study: 19570098

Group type: EXPERIMENTAL
Intervention: Oral dietary supplement containing antioxidants, minerals and glycosaminoglycans
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18162024

Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg q.a.m.
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg q.a.m.
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg b.i.d.
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg q.a.m. (with food)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg b.i.d. (with food)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg q.a.m. (with food)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg q.a.m. without food
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg b.i.d. without food
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg q.a.m. without food
Number of subjects: 647
Study: 15181401

Group type: EXPERIMENTAL
Intervention: Sevoflurane administration for 15 min before coronary occlusion
Number of subjects: 42

Group type: COMPARATOR
Intervention: No sevoflurane administration (Control group)
Number of subjects: 42
Study: 11159479

Group type: EXPERIMENTAL
Intervention: Apraclonidine hydrochloride 1%
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9310564

Group type: COMPARATOR
Intervention: Intravenous ondansetron 4 mg
Number of subjects: 11980

Group type: EXPERIMENTAL
Intervention: Combined data from non-duplicated and duplicated reports
Number of subjects: 11980

Group type: EXPERIMENTAL
Intervention: All original and duplicate reports (n = 25)
Number of subjects: 11980

Group type: EXPERIMENTAL
Intervention: Duplicated data inclusion in meta-analysis
Number of subjects: 11980
Study: 8496205

Group type: EXPERIMENTAL
Intervention: Multiple laminotomy (group I)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Total laminectomy (group III)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Laminotomy converted to laminectomy (group II)
Number of subjects: 67
Study: 3434165

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 58

Group type: COMPARATOR
Intervention: No local treatment
Number of subjects: 58
Study: 31837050

Group type: EXPERIMENTAL
Intervention: SM-1
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 28400446

Group type: EXPERIMENTAL
Intervention: Avacopan (30 mg, twice daily) plus reduced-dose prednisone (20 mg daily)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Avacopan (30 mg, twice daily) without prednisone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo plus prednisone (60 mg daily)
Number of subjects: 67
Study: 25043459

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 µg daily
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combination of teriparatide and denosumab
Number of subjects: 94
Study: 23549780

Group type: EXPERIMENTAL
Intervention: quasi-volumetric modulated arc therapy (qVMAT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy (IMRT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3D-conformal radiation therapy (3D-CRT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: qVMAT with a 0.5 cm ring around the PTV
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IMRT with a 0.5 cm ring around the PTV
Number of subjects: 12
Study: 21739262

Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting (S)
Number of subjects: 40
Study: 19826986

Group type: EXPERIMENTAL
Intervention: Postoperative head bandage (61 patients, 73%)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No head bandage (23 patients, 27%)
Number of subjects: 84
Study: 16705561

Group type: EXPERIMENTAL
Intervention: Additional psychological intervention
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control arm (no additional psychological intervention)
Number of subjects: 224
Study: 15650513

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1182
Study: 10666534

Group type: EXPERIMENTAL
Intervention: Vibration therapy (60 Hz frequency, 45-min treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment (audible hum and lit control box without vibration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All patients (both vibration and sham)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vibration therapy vs. Sham treatment
Number of subjects: 0
Study: 9327190

Group type: EXPERIMENTAL
Intervention: etodolac 200 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: acetaminophen plus codeine (Tylenol #3)
Number of subjects: 40
Study: 8380310

Group type: EXPERIMENTAL
Intervention: Estrogen pretreatment (2.5 mg of conjugated estrogen, Premarin)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No pretreatment (control group)
Number of subjects: 73
Study: 3533271

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (5 mg/kg body weight)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan
Number of subjects: 21
Study: 3124899

Group type: COMPARATOR
Intervention: Diet B (fat reduced diet, 35% energy from fat, P:S ratio 0.5)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Diet C (fat modified diet supplemented with fibre, 27% energy from fat, P:S ratio 1.0)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Diet A (reference diet, 42% energy from fat, P:S ratio 0.2)
Number of subjects: 15
Study: 30943941

Group type: EXPERIMENTAL
Intervention: Free breakfast club intervention
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 318
Study: 28881387

Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) and lactoperoxidase (LPO) containing tablets
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 46
Study: 25987323

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment during double-blind trials and a 6-month open-label phase
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ADHD emotional dysregulation presentation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ADHD inattentive presentation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cluster analysis
Number of subjects: 100
Study: 23242356

Group type: COMPARATOR
Intervention: Harm Avoidance in PD patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Novelty Seeking, Reward Dependence, and Persistence in PD patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cognitive flexibility
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Divergent thinking and inhibition
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Novelty Seeking
Number of subjects: 43
Study: 21463169

Group type: EXPERIMENTAL
Intervention: Dynamic Interpersonal Therapy (DIT)
Number of subjects: 16
Study: 18981043

Group type: EXPERIMENTAL
Intervention: Coordinated multiple strategies designed to address individual, interpersonal and environmental determinants of physical activity
Number of subjects: 0
Study: 16391578

Group type: EXPERIMENTAL
Intervention: Electronic visual analogue scale (VAS) system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional pen and paper version of the questionnaire
Number of subjects: 20
Study: 12736118

Group type: EXPERIMENTAL
Intervention: Cigarette smoking for 40 years or more
Number of subjects: 89835

Group type: EXPERIMENTAL
Intervention: Cigarette smoking of shorter duration
Number of subjects: 89835

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (general)
Number of subjects: 89835

Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 89835
Study: 10764905

Group type: EXPERIMENTAL
Intervention: Auditory event-related potential (ERP) in PD
Number of subjects: 12

Group type: COMPARATOR
Intervention: Auditory event-related potential (ERP) in control subjects
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: P300 amplitude analysis
Number of subjects: 12
Study: 9284855

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (4 micrograms/kg/min) + low-dose furosemide (80 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (4 micrograms/kg/min) + medium-dose furosemide (5 mg/kg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-dose furosemide (10 mg/kg/day)
Number of subjects: 20
Study: 8398589

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg orally)
Number of subjects: 9
Study: 2945420

Group type: EXPERIMENTAL
Intervention: 10 mg nicorandil
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 30 mg nicorandil
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 28400368

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 6763

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 6763
Study: 26285584

Group type: EXPERIMENTAL
Intervention: Met DR 600 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Met DR 800 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Met DR 1,000 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Met XR 1,000 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Met XR 2,000 mg
Number of subjects: 240
Study: 25198310

Group type: EXPERIMENTAL
Intervention: Multi-component exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium and vitamin-D3 intervention
Number of subjects: 0
Study: 22377939

Group type: EXPERIMENTAL
Intervention: Hyperoxic training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normoxic training
Number of subjects: 16
Study: 19671306

Group type: EXPERIMENTAL
Intervention: Hp positive group
Number of subjects: 130
Study: 18075922

Group type: EXPERIMENTAL
Intervention: Brief intervention package for hazardous drinkers; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition; details not specified.
Number of subjects: 0
Study: 15077240

Group type: EXPERIMENTAL
Intervention: Zydis selegiline 1.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zydis selegiline 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zydis selegiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zydis selegiline and placebo
Number of subjects: 0
Study: 12111129

Group type: EXPERIMENTAL
Intervention: Deferoxamine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 13
Study: 10214575

Group type: EXPERIMENTAL
Intervention: ADCON‐L
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 7594015

Group type: EXPERIMENTAL
Intervention: Glass ionomer
Number of subjects: 123

Group type: COMPARATOR
Intervention: Spherical amalgam
Number of subjects: 123

Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 123
Study: 2375289

Group type: EXPERIMENTAL
Intervention: Strenuous exercise (90 W)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moderate exercise (30 W)
Number of subjects: 18
Study: 7251221

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment (20 mg twice daily for 2 years)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Postoperative adjuvant radiotherapy or chemotherapy
Number of subjects: 270

Group type: COMPARATOR
Intervention: ER content levels (high, intermediate, low)
Number of subjects: 270
Study: 31481299

Group type: EXPERIMENTAL
Intervention: Female patients with bladder cancer
Number of subjects: 24169

Group type: EXPERIMENTAL
Intervention: Nonmuscle-invasive and muscle-invasive bladder cancer subgroups
Number of subjects: 24169

Group type: COMPARATOR
Intervention: Baseline differences in age, tumor, node, and metastasis-stage and histology
Number of subjects: 24169
Study: 28988904

Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation (DBS) targeting bilateral subcallosal cingulate white matter
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation (DBS)
Number of subjects: 90
Study: 27686349

Group type: EXPERIMENTAL
Intervention: Fluid restriction protocol
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard care protocol
Number of subjects: 151
Study: 23834272

Group type: EXPERIMENTAL
Intervention: 78 kPa stress
Number of subjects: 8

Group type: COMPARATOR
Intervention: 4 kPa stress
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both 78 kPa and 4 kPa
Number of subjects: 8
Study: 23328162

Group type: EXPERIMENTAL
Intervention: Naftopidil (Naf) 50-75 mg once daily for 2 weeks followed by 75 mg once daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silodosin (Silo) 2-4 mg twice daily for 2 weeks followed by 4 mg twice daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silodosin (Silo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naftopidil (Naf)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naftopidil (Naf) and Silodosin (Silo)
Number of subjects: 0
Study: 19389333

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17491099

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 61
Study: 15469803

Group type: EXPERIMENTAL
Intervention: Oral deflazacort (1.5 mg/kg) for 7 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Oral prednisolone (1 mg/kg) for 7 days
Number of subjects: 54
Study: 11271455

Group type: EXPERIMENTAL
Intervention: Soft contact lens wearers (short-term, intermediate-term, long-term)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Soft contact lens wearers (more than 6 years)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Soft contact lens wearers (all subgroups)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-contact lens wearers (control group)
Number of subjects: 90
Study: 10399518

Group type: EXPERIMENTAL
Intervention: Epidural block (caudal) with 11-15 ml of 2% lidocaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural catheter insertion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Radiological study with iohexol contrast medium
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia supplementation
Number of subjects: 10
Study: 7992812

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2732620

Group type: EXPERIMENTAL
Intervention: High-protein diet (2 gm/kg/day)
Number of subjects: 9
Study: 31501039

Group type: EXPERIMENTAL
Intervention: Home Automation training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional training based on face‐to‐face interaction and practical activities
Number of subjects: 40
Study: 30362137

Group type: EXPERIMENTAL
Intervention: Extra-short implants (≤6 mm)
Number of subjects: 1612

Group type: COMPARATOR
Intervention: Long implants (≥10 mm)
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1612
Study: 29349999

Group type: EXPERIMENTAL
Intervention: Epidural injection of Diprospan, Lidocaine, and Mecobalamine after PELD
Number of subjects: 126

Group type: COMPARATOR
Intervention: Normal saline injection after PELD
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both groups (PELD with and without epidural injection)
Number of subjects: 126